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Purpose: The ENCePP Code of Conduct provides a framework for scientifically inde-
pendent and transparent pharmacoepidemiological research. Despite becoming a land-
mark reference, practical implementation of key provisions was still limited. The fourth
revision defines scientific independence and clarifies uncertainties on the applicability
to postauthorisation safety studies requested by regulators. To separate the influence
of the funder from the investigator's scientific responsibility, the Code now requires
that the lead investigator is not employed by the funding institution.
Method: To assess how the revised Code fits the ecosystem of noninterventional
pharmacoepidemiology research in Europe, we first mapped key recommendations
of the revised Code against ISPE Good Pharmacoepidemiology Practices and the
ADVANCE Code of Conduct. We surveyed stakeholders to understand perceptions
on its value and practical applicability. Representatives from the different stake-
holders' groups described their experience and expectations.
Results: Unmet needs in pharmacoepidemiological research are fulfilled by provid-
ing unique guidance on roles and responsibilities to support scientific independence.
The principles of scientific independence and transparency are well understood and
reinforce trust in study results; however, around 70% of survey respondents still
found some provisions difficult to apply. Representatives from stakeholders' groups
found the new version promising, although limitations still exist.
Conclusion: By clarifying definitions and roles, the latest revision of the Code sets a
new standard in the relationship between investigators and funders to support
scientific independence of pharmacoepidemiological research. Disseminating and
training on the provisions of the Code would help stakeholders to better understand
its advantages and promote its adoption in noninterventional research.
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KEY POINTS
• The Code is a unique source of practical guidance on
scientific independence and transparency in the
relationship between investigators and funders.
• The Code's fourth revision supports the scientific
integrity of noninterventional postauthorisation research.
• Compliance with the Code protects researchers and
study funders from threats to scientific independence
related to commercial, financial, institutional, or personal
interests.
• Researchers, from the funding organisation shall not
participate in study activities that could influence the
results or their interpretation in any particular direction.
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The European Network of Centres for Pharmacoepidemiology and
Pharmacovigilance (ENCePP) was set up in 2008 to strengthenmethod-
ological standards, transparency, and scientific independence that sup-
ports the evaluation of medicines in Europe.1 The ENCePP Code of
Conduct, referred to hereafter as the Code, was first released in 2010
to set out a framework for good practise in the relationship
between investigators and study funders, irrespective of whether the
study funder was a public body, industry, or a regulatory authority.2
The purpose was ultimately to improve the integrity of
pharmacoepidemiological research, for the benefit of public health.
The ENCePP Code of Conduct is a tool supporting the dialogue
between stakeholders in pharmacoepidemiological studies. The
objective of this paper is to present the main provisions of the
Code, focussing on the most recent revision, and to discuss the
perspectives of the relevant stakeholders on its value and
applicability.2 | THE ENCEPP CODE OF CONDUCT
2.1 | The initial concept
The initial concept for the Code was a contractual framework between
the study funder and the primary lead investigator that would seek to
guarantee transparency and scientific independence. However,
because of the different languages and legal systems existing across
Europe, a standard template for the research contract between a
research institution and a study funder was not deemed feasible, and
the Code was launched as a set of principles and provisions to be
integrated in each study contract. The contract was to be signed
before the development of the study protocol.
A key requirement was the publication of study results, whether
negative or positive, under the responsibility of the primary lead
investigator. Transparency was granted by the creation of a publicly
accessible electronic register, which later became the European Union
(EU) Post‐Authorisation Studies (PAS) Register (EU PAS Register), in
which the study protocol was to be uploaded before data collection
and in which the study report was to be uploaded when the study is
finalised.
Since 2010, several revisions of the Code were published in light of
experience with its uptake by stakeholders and in efforts to facilitate
the implementation of its requirements on access to study data,
declaration of interests, and funding sources; to improve its readabil-
ity; and to provide clarifications.
Despite these revisions and whilst becoming a key reference for
the conduct of pharmacoepidemiological studies over the years, the
Code continued to experience limitations in its use. In hindsight, chief
amongst them was the lack of definition of scientific independence,
which made it difficult to verify its implementation by involved parties,
despite their commitment. Secondly, the concept of the “ENCePP
Seal,” developed as an option to formalise both the commitmentto the Code and the application of ENCePP methodological stan-
dards,3,4 was often misunderstood as suggesting that some provisions
of the Code were optional and would only apply if the Seal was
requested. Thirdly, the principle of conflict of interest referred almost
exclusively to financial or commercial interests without considering
the importance of the influence that institutional or personal inter-
ests may have on outcomes of research.5 And finally, the Code had
initially been created before the EU pharmacovigilance legislation
came into force in 2012 and experience with the implementation
of this meant that clarifications were needed as to how some provi-
sions would apply to postauthorisation safety studies (PASS).6 A
major revision of the Code was therefore undertaken in 2017 and
completed in 2018.2.2 | The fourth revision
The key changes to address these deficiencies in the fourth revision
are as follows. The spirit of the revision was to further move the
balance from principles to practical solutions.2.2.1 | New definition of scientific independence
After much deliberation, scientific independence is now defined as fol-
lows: that any financial, commercial, institutional, or personal interest
in a particular outcome of the study (ie, in the results and their
interpretation) at the level of the organisation initiating or funding
the study and of the researcher(s) conducting the study, shall not
influence any decision on the scientific aspects of the study in any
particular direction, including the data collection and the analysis,
interpretation, and dissemination of the study results.
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interest
Four categories of relevant interests are described: commercial, finan-
cial, institutional, and personal. In particular, it is now specified that
commercial interests refer to the interests of organisations marketing
the drug under study. The provisions of the Code now invest the four
categories in a more articulated way.
Indeed, in the previous version of the Code, the requirement was
that after protocol finalisation, no person with a commercial, financial,
institutional, or personal interest in a particular outcome of the study
could take part in any study activity that could influence the results
or interpretation in any particular direction. This provision was consid-
ered as having undesired consequences and was modified in the
current revision. Currently, all members of the study team are first
requested to declare all existing direct and potential indirect interests
of a commercial, financial, institutional, or personal nature that might
impact their impartiality in relation to the study, and their declarations
must be made available in the EU PAS Register. Second, specific pro-
visions concern commercial, financial, or institutional interests only:
persons with such interests may not take the role of the primary lead
investigator and may not participate in activities after protocol
finalisation that may impact the results or their interpretation, unless
no other specific technical expertise needed for the conduct of the
study can be obtained in the study team. In addition, they may not
have a decision‐making role in the meetings of the steering group (if
applicable), where they may be invited as specialists.
2.2.3 | Supporting applicability in regulatory studies
For studies requested by a regulatory authority to which legal require-
ments apply, the Code specifies that the final protocol should be
agreed between the primary lead investigator, the study funder and
the competent authority, even if the final responsibility of the protocol
remains with the primary lead investigator. This provision comple-
ments the Good Pharmacovigilance (see: https://www.ema.europa.
eu/en/human-regulatory/post-authorisation/pharmacovigilance/
good-pharmacovigilance-practices) Practices (GVP) Module VIII
requirement that the study protocol should be developed by individ-
uals with appropriate scientific background and experience.6
2.3 | Comparison with other guidelines
In order to assess how the fourth revision fulfils an unmet need in
pharmacoepidemiological research, we mapped the main recommen-
dations of the revised Code with those of the International Society
for Pharmacoepidemiology (ISPE) Good Pharmacoepidemiology
Practices (GPP)8 and of the ADVANCE Code of Conduct.9 Table 1
provides the main recommendations from each guideline for the main
topics addressed by the Code.
Although there are similarities between the three guidelines, there
are also important differences explained by their differing objectives:
the Code aims to establish the concepts of scientific independenceand transparency in the relationship between investigators and study
funders, the ISPE GPP aims to ensure the scientific quality and integrity
of pharmacoepidemiological studies and the ADVANCE Code of Con-
duct aims to support effective collaborations in postauthorisation vac-
cine studies. An important difference exists between the Code and the
ISPE GPP as regards the principle of scientific independence. The latter
states that (a) organisations and individuals conducting and sponsoring
the research shall be fully responsible for the research; (b) for projects
sponsored by one organisation (such as a pharmaceutical company or
government agency) but implemented by another (eg, academic institu-
tion), the responsibility for scientific integrity is shared between the col-
laborating institutions; and (c) the primary lead investigator is
responsible for the overall content of the research. The European legis-
lation defines the term “sponsor” as an individual, company, institution or
organisation which takes responsibility for the initiation, management
and/or financing of a clinical trial.10 This makes the previous statements
difficult to map to the context of noninterventional studies in Europe,
and as a result, no support in the relationship between funders and
investigators on the topic of scientific independence is provided. The
Code therefore represents a unique source of guidance on this critical
aspect of pharmacoepidemiological research in Europe. A recent com-
mentary endorsed by the ISPE Board outlined points to be incorporated
in academia‐industry agreements in order to facilitate collaborative
pharmacoepidemiological research.11 It does not provide recommenda-
tions on how to implement these considerations as these will depend
on the specific research setting. The ENCePP Code of Conduct pro-
vides such practical recommendations for the European situation, but
they may also be considered for other settings if applicable.2.4 | Clearer distinction between the Code and the
ENCePP Seal
Researchers not requesting an ENCePP Seal but intending to comply
with the Code must follow exactly the same provisions as those
requesting the Seal. In order to convey this message, all the proce-
dures required to obtain the ENCePP Seal were removed from the
Code and transferred into a separate document.73 | STAKEHOLDERS' OPINION
3.1 | Survey of stakeholders
After release of version four, a survey of stakeholders was conducted
to evaluate how potential users understand and apply the Code in
practise. This survey was only marginally referring to the revised ver-
sion, and the topic was more generally the high‐level concept of the
Code. Five categories of stakeholders were identified: patient and
consumer organisations, health‐care professionals, pharmaceutical
industry, public health body or regulators, and researchers (academic,
contract research organisations, and other type of research profes-
sionals not employed by pharmaceutical industry). They were invited
to provide feed‐back on the following five dimensions:
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428 GINI ET AL.• Usefulness: for which types of studies the Code was considered to
be beneficial
• Clarity: whether the Code was considered to be clear
• Trust: whether application of the Code was increasing trust in a
study
• Participation: whether the respondent would more likely participate
in a study if it were compliant with the Code
• Redundancy: whether the Code was perceived as redundant with
other guidelines
For some dimensions, the questions were tailored to stakeholder
categories to match their perspective and expected level of expertise
in the field of noninterventional postauthorisation studies. The full
questionnaire is available as supplement. The survey was conducted
online with the EU Survey tool and distributed by the European Med-
icines Agency (EMA). A snowball sampling strategy was enacted, and
in particular, ENCePP partners and stakeholder representatives and
observers within the Steering Group were requested to share the sur-
vey link with individuals within and outside of their own organisations.
After 1 month, a total of 87 responses were received. The most
represented category of respondents (43 or 49%) was “researchers,”
and the least represented one was “patients and consumer organisa-
tions” (6 or 7%). On average, respondents assessed their knowledge
about noninterventional postauthorisation studies as “fairly good”
(33 or 37.9%) or “expert” (31 or 35.6%).
In the “usefulness” dimension, the majority of the respondents
overall indicated that the Code would benefit all or most of all studies
(66 or 76%)
Regarding “clarity,” patients and healthcare professionals were
asked (a) if they understood and (b) if they found important the prin-
ciples of scientific independence and transparency, and the answers
were largely positive to both questions (14 or 87.5% and 15 or
93.7%, respectively). Respondents from the other categories were
asked to rate the Code in terms of easiness to understand and apply.
The former was judged positively by a large majority of respondents
(92%), whilst in the latter, a negative judgement prevailed in all
categories (70%) but more so amongst pharmaceutical companies
(88%). In the dimension of “trust,” a large majority of respondents
in all categories (83%, 69% in pharmaceutical industry) responded
that the Code would reinforce their trust in the study results. In
the “participation” dimension, a large majority (71%) declared that
studies applying the Code were likely to encourage their participa-
tion (in the role corresponding to their category), except for pharma-
ceutical industry, where half of the respondents (50%) replied with a
neutral or negative answer. In the dimension of “redundancy,”
the overlap with other guidelines was difficult to judge by half of
the sample of patients and health professionals and by 42% in the
category of public health body or regulators. Amongst those
providing an answer, the majority (38 or 43.7% of the whole sample)
considered that the Code is a good complement to other guidelines.
A complete report of the survey is available in the EU PAS Register
(EUPAS26545).3.2 | ENCePP stakeholders' perspective
The following section provides the perspective of the different stake-
holder groups of ENCePP based on the individual experience of the
co‐authors: H.D. is a senior member of ENCePP Working Group 2
and one of the coauthors of the initial Code; X.F. is a member of the
Board of the European CRO Federation; P.V. and K.A. are representa-
tives of their respective stakeholder groups in the ENCePP Steering
Group; V.S. is an appointed expert and former alternate member of
the Pharmacovigilance Risk Assessment Committee (PRAC).
3.2.1 | Academic perspective
Scientific independence and transparency are considered well
established principles in academic research. However, there has been
increasing realisation of the ways in which unconscious bias can
occur.2,5,12-14 Some of these problems relate to the quality of the
research process (eg, adherence to the principles of stating hypothe-
ses in advance, clarifying the protocol in advance, not selecting
preferred results, following best practise in analysing and reporting
results, always publishing results whether positive or negative). Trans-
parency involves all stakeholders being able to verify that best practise
in research process has been followed. Other problems relate to real
or perceived pressure from study funders or ambiguity in how the
interpretation of results or their reporting is influenced by particular
interests in study outcomes. Scientific independence therefore needs
to be visibly strengthened. These problems have damaged public
confidence in scientific integrity of researchers and the validity of
research results, and thus academic stakeholders can only welcome a
Code, which not only promotes scientific independence and transpar-
ency but also gives researchers a way of publicly certifying their own
adherence to these principles and an externally validated way of nego-
tiating with funders how compliance with them can be substantiated
in practise.
The disadvantages of the Code from an academic perspective have
been mainly the time resources needed to comply with the transpar-
ency provisions of the Code and to enact the Code in the funding con-
tract. Rather than following the Code for all studies, it is likely to be
felt to be particularly important and worth the time investment where
the funder is industry. Multistakeholder engagement in the protocol
refinement process is likely to be a path to greater relevance and
impact of the research, but it also imposes a greater complexity of
understanding and managing interests.
A grey area is still the exact point at which the contract is signed in
relation to prior feasibility studies and the exact nature of those feasi-
bility studies since the period before the contract is not covered by
the Code. Some protection in studies, which go ahead to contract, is
given by including prior feasibility studies transparently as part of
the protocol.
From an academic perspective, a greater awareness and more
explicit value placed on the Code by medical journals would be helpful,
both in justifying the expenditure of resources in following the Code
and in negotiating compliance with the Code with funders. Academics
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currently self‐policed, and the resulting impact on public confidence
may not be as high as desired. Further development of a compliance
monitoring mechanism could be envisaged.
Finally, from an academic point of view, the issue of scientific
independence and transparency will never be fully resolved, whilst
industry retains so much of the responsibility for conducting medica-
tion safety (and benefit) research. If regulatory agencies were to fund
more of this to be done in the public sphere, with industry contribut-
ing to a public funding pot, which was distributed via an independent
public mechanism, this could meet the requirement of scientific inde-
pendence and achieve efficiencies that are impossible with the current
product‐centred pharmacovigilance system.
3.2.2 | Industry perspective
There is general agreement on the key principles of scientific indepen-
dence and transparency; however, the practical implementation of
these principles for industry‐funded studies performed for regulatory
purposes is challenging.
In the previous version of the Code, a key issue was the interpre-
tation that the Code did not allow involvement in the study conduct
after protocol approval, even when the study funder was legally
responsible to comply with regulatory requirements. From an industry
perspective, the sponsor's or marketing authorisation holder's legal
accountability cannot be transferred to a third party. Related to this,
another aspect was that the epidemiological expertise of researchers
employed by industry that adds value to a study as does the expertise
from academic researchers was not really considered. In this respect,
the Code's focus on conflicts of interest of the study funder was con-
sidered as not balanced, and conflicts of interest that may arise from
personal interests of researchers seemed to be perceived less of a
threat to scientific integrity.
For all these reasons, a revision of the Code was welcomed by
industry in order to get a more clear definition of scientific indepen-
dence; ensure that industry can fulfil its legal obligations in following
the Code; allow some flexibility in the study team structure, as defined
in the research contract; and support better collaboration, as well as
increase the trust, between all involved stakeholders.
With the updated current version of the Code, some of the previ-
ous critics should be now obsolete. The changes introduced may ease
the use of the Code when industry is the funder, even if this will be
difficult to quantify. This is why it could be interesting to develop a
metrics that would help to assess how often the Code is implemented,
for which types of studies (required by regulators or not), from which
funder. This could be implemented in the EU PAS Register. This would
most probably be easier to implement than assessing the real compli-
ance with the content of the Code.
3.2.3 | Contract research organisation perspective
The Code was so far not explicit on whether contract research organi-
sations belonging to ENCePP could participate in a study compliantwith the Code beyond protocol finalisation. CROs are usually for‐
profit private organisations providing scientific expertise in the proto-
col design, recruitment, monitoring, data management and analysis,
study report, and publication of results. The new definition for conflict
of interest usefully clarified that the outcome of a specific study being
in one direction or another is not intended to be a commercial interest
of the CRO or academic institution involved in the research contract.
3.2.4 | Regulatory perspective
Since its beginning, the ENCePP network has served as support for
the European regulatory environment in the field of epidemiol-
ogy.1,15,16 The ENCePP network has also helped to facilitate the intro-
duction of amended regulatory concepts and amended frameworks
specifically in the field of epidemiology for the conduct of
postauthorisation safety studies (PASS), and especially following also
regulatory requirements coming into force with the EU
pharmacovigilance legislation in 2012.17-19 Evolution of the ENCePP
network continues to support the work of EU regulatory agencies
mirroring also the increased demand for generation of post‐approval
data.17,20 ENCePP guidance documents are seen as important
resource and form part of recommended references and resources
of regulatory guidance such as GVP Modules.
The Code may be applied to studies requested or imposed by reg-
ulatory authorities. A recent review showed that only a limited num-
ber of PASS protocols discussed at EMA's PRAC had the ENCePP
Seal, implying declared application of the Code.21 Studies imposed
on MAHs as a condition of marketing authorisation are generally over-
seen by regulators with the possibility to influence study design and
protocol development. From a regulatory perspective, the application
of the Code might be seen as less relevant if regulatory oversight is
ensured. However, strengthened transparency and independence with
regard to the role of investigators may still be important, although it is
acknowledged that regulatory agencies would prioritise regulatory
compliance and implementation of provisions imposed for such stud-
ies. This implies that primary lead investigators are not completely
independent in terms of the conduct of imposed studies as objectives
and aspects of study designs are rather inflexible based on binding
conditions. Early engagement with all stakeholders in protocol discus-
sions might ensure understanding of the regulatory requirements and
avoid deviation from study concepts and delays in protocol approval
by regulators.
The provisions of the Code foreseeing that studies requested by
regulators are not only agreed with the study funder but also with
the competent authority(ies) strengthens the scientific independence
of the primary lead investigator, which seems particular important
for studies funded by stakeholders with interests in the products
investigated. Whilst it might be considered as additional burden, the
opportunity to engage with the primary lead investigator at the early
stages of protocol discussions might also help to improve the process
of protocol agreement, to foster timely involvement in discussions of
methodological, operational, and feasibility aspects and to decrease
possible information loss when regulatory advice is only conveyed
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responsible study investigator. Such issues led to multiple rounds of
regulatory comments on PASS protocols,21 prolonging the process of
protocol approval.
Regulatory agencies also frequently assess results of
noninterventional studies that were not conducted based on regula-
tory requests. For these studies also, assurance of transparency and
independence are important factors guiding considerations of assess-
ment of these data.
It has to be further noted that strengthened concepts of transpar-
ency and independence of study investigators might help to meet
critique that has been expressed regarding the conduct of epidemiolog-
ical studies, including PASS.22,23 The generation of epidemiological
evidence is sometimes relevant to support the early approval of
medicines. This highlights the need for reinforcement of those con-
cepts, to enhance trust in postapproval epidemiological research.17,24
Trust building is further supported by increased transparency and
the Code's provision to enter studies in the EU PAS Register. Apart
from study registration, the Code foresees publication of study proto-
cols and study results. A sample of German national PASS notified to
the Federal Institute of Drugs and Medical Devices (BfArM) between
January 2015 and June 2018 showed that 90% of the studies had
been entered into the EU PAS Register with about 56% of those with
a protocol published. For studies for which BfArM received an “end of
study” notification between January 2015 and June 2018 about 62%
had results published via the EU PAS Register. However, 36% pro-
vided only abstract information, and only 25% made comprehensive
study reports available. This provides room to further increase
transparency in line with the provisions of the Code. A broader and
more frequent application of the Code's transparency provisions by
all stakeholders is necessary to further strengthen transparency in
postauthorisation research, a concept also pursued by the EU
pharmacovigilance legislation.19
New emphasis has been put on performing joint PASS
encompassing studies performed by multiple marketing authorisation
holders, which is also covered by the Code. Whilst it is acknowledged
that conduct of joint studies may be associated with higher burden
for stakeholders, especially during protocol development, from a scien-
tific and regulatory perspective, the conduct of joint PASS is preferred
over the generation of fragmented results by multiple stakeholders.
This is particularly the case when study objectives relate to a substance
or therapeutic class independent of a product or marketing authorisa-
tion holder, eg, assessing the impact of risk minimisation measures
introduced postapproval through safety referrals. Despite frequently
recommended by regulators, the conduct of joint PASS remains
sparse.21 The Code's provisions for practical implementation of scien-
tific independence might help to overcome constraints of individual
industry stakeholders who wish to engage in joint PASS concepts.
3.2.5 | Patient and consumer perspective
Despite the importance of the role of ENCePP and the interest that
patient advocacy groups expressed in the recent years in drugdevelopment, clinical trials, drug safety, and adverse events of their
medicines, ENCePP is little known to the European patients and con-
sumer organisations at large, and it would not be arbitrary to include
health care professionals.
This assumption was validated by the results of the stakeholder
survey mentioned earlier with only 7% of respondents from patient
and consumer organisations, compared with 49% of respondents
being researchers. The lack of familiarity with the activities and the
role of ENCePP amongst the European patient community are
reflected in the answers to the survey. Noninterventional
postauthorisation studies are less known amongst patients and con-
sumers than amongst the other participant groups. What is worth
noting is that despite low level of knowledge about ENCePP,
patients and consumers together with the other responder groups
confirmed the usefulness dimension of the Code, as being beneficial
to all or most of the studies, and the importance of the principles of
scientific independence and transparency. It is worth noting that
the latter two principles are supported by the vast majority of
European umbrella patient organisations, as proven by their advo-
cacy about them.
Patients value highly scientific independence, meant as not linked
to any financial or other interests and assuring quality research
financed from external sources. Equally, transparency is very
important for patient organisations who have claimed recently the
publication of all results of clinical studies, regardless of whether they
are positive or negative. The adoption by ENCePP of these principles
adds to its credibility and its perception by the public as a trustworthy
scientific organisation.
Patients are indeed more interested in the results; however, they
are much concerned about the methodology to carry out a study,
which is affecting its results. To this end, the principles and the set
of rules governing the Code increase the confidence and trust of
patients and citizens in the integrity and value of studies carried out
by ENCePP.
Studies that bear the ENCePP Seal are considered as more trust-
worthy and having undergone close scrutiny as to compliance with
ENCePP principles and rules. However, even if patients and the public
generally understand what scientific independence and transparency
with regard to medicines mean, there are serious doubts that they
fully understand the meaning of these terms in the context of the
ENCePP Code of Conduct.
All major European patient umbrella organisations recognise the
need of rules governing their relations with the scientific community,
study funders, and regulators, and amongst them, concrete and
unequivocal recruitment rules, informed consent, and ethical aspects
are considered of particular importance. Transparency, clarity,
unequivocal terms, and respect of ethical aspects are very important
for patients.
As the set of rules and principles for pharmacoepidemiology and
pharmacovigilance studies to promote transparency and scientific
independence throughout the research, the Code should be well
known and understood by all those involved in one way or another
with medicines, including the general public as the end users. As the
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communication strategy to these audiences should be tailored to their
needs and expectations from the studies covered by the Code.4 | DISCUSSION
The fourth revision of the Code introduced new provisions aimed at
supporting scientific independence and transparency in studies funded
by an external institution. Its focus is on studies that involve at least
two institutions that are tied by a research contract and a remunera-
tion agreement. The study funder is often an institution with a
commercial, financial, or institutional interest in the study results, but
it often has also the responsibility for selecting the research institution
that will lead the study, and it can influence the course of the study
itself. The Code therefore foresees a separation between the
influence of the funder and the scientific responsibility of the study,
and for this reason, the primary lead investigator may not belong to
the institution that funds the study (irrespective of the nature of the
funding institution). This implies that studies conducted by an
organisation based on its own funding may not be compliant with
the Code as the precautionary separation between funder's influence
and scientific responsibility is not implemented. This does not imply
that such studies are invalid.
By forbidding important roles to researchers with personal inter-
ests, the previous version of the Code may have led candidate inves-
tigators to claim they had no interests rather than conducting an
honest analysis of their personal position with respect to the study
outcomes. This left the impression that the Code was only focussing
on financial and commercial interests. Indeed, there are legitimate
inclinations of personal nature that, if undetected, may lead to an
unwanted influence. For instance, a finding that is unexpected or
novel, or unfavourable to a drug, may be more appealing for
publication and may therefore constitute a personal interest of an
investigator working in academia.5
Although it was not representative of the views of an entire
stakeholder group, the survey indicated that all the categories of
stakeholders considered the Code as beneficial to all the studies, but
practical applicability was indicated as problematic, and judging
overlap with other guidelines was considered difficult. We showed,
however, that, in comparison with the ISPE GPP and the ADVANCE
Code of Conduct, the ENCePP Code of Conduct is a unique source
of guidance on scientific independence and relationships between
investigators and study funders. A major concern from an industry
perspective was that the Code would forbid industry to fulfil its legal
obligation in case of regulatory requirements as, after protocol
finalisation, the Code excludes participation of researchers from the
funding organisation in study activities “that could influence the
results or interpretation thereof in any particular direction.” It must
be noted, however, that this provision does not preclude a regular
monitoring of the progress of the study, for example, in terms of mon-
itoring recruitment and data quality such as missing data levels or lossto follow‐up. On the contrary, the Code specifies that the investiga-
tors have the obligation to keep the funder informed of such data.4.1 | Limitations of the Code
The expression “commercial interest in an outcome of the study” is
clarified in the Code to refer to the legitimate interest of those organi-
sations marketing drugs. However, it may be perceived that research
institutes that rely on funding from pharmaceutical companies to
thrive (if public or private not‐for‐profit) or to pursue their legitimate
profit (if for‐profit), may be subject to indirect, possibly unwanted,
influence from their funders. Even though compliance with the Code
does protect researchers and funders from this risk within the realm
of a single study, it cannot avoid a more subtle influence, because of
a perception that funders may select the institution, which will con-
duct the next study based on the result of previous studies, instead
of professional reputation. A related risk is that investigators and
researchers may be tempted to interpret evidence of negative results
as need for further research, with the objective of attracting new
funding. In Europe, according to the current legislation, the funders
for pharmacoepidemiology studies requested by regulators are mostly
manufacturers themselves, which are therefore the most common
funders for European research institutions in pharmacoepidemiology.
This makes the risk of indirect influence higher than in the United
States, where public funding is substantial. The ADVANCE project
attempted to address the indirect influence of study funders, by
producing guidance on the selection of research institutions. Three
models of selection were proposed, in increasing order of perceived
independence: led by the study funder, led by a selection committee,
led by an external body.254.2 | The way forward
The Code is perceived as useful but, at the same time, has to date
been seen as potentially difficult to apply in practise. As discussed
above, this is partly due to the inherent complexity of the relationships
between study funders and investigators. It is hoped that the current
major revision will help in clarifying and disseminating the provisions
of the Code to support understanding of its advantages and promote
its adoption. Examples of translation of principles of the Code into
concrete actions should be made available that could also support
training activities.13 To reinforce trust in the actual application of the
Code's provisions funders and investigators may decide to enter in
the EU PAS Register together with the final study report, a final self‐
assessment of compliance with the Code, signed by all involved
parties. Alternatively, an independent scientific committee overseeing
the study conduct could also take the responsibility to review
compliance with the Code. A periodic, independent review of a
random sample of EU PAS Register records would also be useful.
Finally, to address the limitations of the Code and building on previous
work, ENCePP could develop specific guidance on the selection of
research institutions.
432 GINI ET AL.5 | CONCLUSION
The ENCePP Code of Conduct is a tool supporting
pharmacoepidemiology studies. Researchers are supported in their
relationship with study funders, as scientific collaboration is allowed
within limits and under their control, as well as with regulators, as
the Code supports dialogue between researchers, regulators, and
funders having to comply with a legal obligation. The pharmaceutical
industry is supported with guidance on practical aspects of the
funding of studies that are considered scientifically independent and
transparent, in particular for regulatory obligations. Regulators are
supported by increasing their confidence in results of studies con-
ducted to best practise of transparency and scientific independence.
And health‐care professionals and patients may have more trust in
studies that generate the evidence they rely upon for their decisions
on pharmaceutical treatments.ETHICS STATEMENT
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